"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
| Descriptor ID |
D014859
|
| MeSH Number(s) |
D03.383.663.283.446.520.914 D03.633.100.150.446.520.914
|
| Concept/Terms |
Warfarin- Warfarin
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
|
Below are MeSH descriptors whose meaning is more general than "Warfarin".
Below are MeSH descriptors whose meaning is more specific than "Warfarin".
This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 3 | 4 |
| 2008 | 1 | 4 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 3 | 1 | 4 |
| 2011 | 3 | 2 | 5 |
| 2012 | 6 | 1 | 7 |
| 2013 | 2 | 1 | 3 |
| 2014 | 6 | 0 | 6 |
| 2015 | 4 | 0 | 4 |
| 2016 | 4 | 3 | 7 |
| 2017 | 3 | 3 | 6 |
| 2018 | 2 | 1 | 3 |
| 2019 | 5 | 1 | 6 |
| 2020 | 2 | 2 | 4 |
| 2021 | 0 | 5 | 5 |
| 2022 | 1 | 3 | 4 |
| 2023 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Warfarin" by people in Profiles.
-
Outcomes Associated With Novel Oral Anticoagulants and Warfarin in Patients With Cardiac Thrombus Following ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2025 Feb 01; 236:72-78.
-
Direct Oral Anticoagulants for Rheumatic?Heart Disease-Associated Atrial Fibrillation Post-Bioprosthetic Mitral Valve Replacement. JACC Clin Electrophysiol. 2024 Dec; 10(12):2701-2710.
-
A meta-analysis of direct oral anticoagulants vs warfarin for left ventricular thrombus. Prog Cardiovasc Dis. 2024 Jul-Aug; 85:114-117.
-
Severity of Ischemic Stroke After Left?Atrial Appendage Closure vs Nonwarfarin Oral Anticoagulants. JACC Clin Electrophysiol. 2024 Feb; 10(2):270-283.
-
Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study. Eur Heart J Qual Care Clin Outcomes. 2023 09 12; 9(6):621-631.
-
Unleashing ferroptosis for cancer therapy with warfarin. Trends Endocrinol Metab. 2023 11; 34(11):683-684.
-
Bleeding outcomes and management of supratherapeutic episodes secondary to warfarin in children: A single center 10-year experience. Thromb Res. 2023 08; 228:148-150.
-
Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. J Thromb Haemost. 2023 06; 21(6):1601-1609.
-
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation. 2022 12 06; 146(23):1735-1745.
-
A new frontier in left atrial appendage closure. Catheter Cardiovasc Interv. 2022 11; 100(5):929-930.